AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03909971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorlatinib
Description: ALK inhibitor-treated ALK-positive NSCL treatment
Study NCT01883518 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous dendritic cell vaccine
Description: Autologous dendritic cell vaccine loaded with allogeneic tumor lysate expression of cancer testis antigens
Study NCT03904043 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: -Monday-Friday treatment is strongly recommended
Study NCT03904043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX regimen
Description: -CAPOX can be given as alternative
Study NCT02536729 — intervention group
Intervention type: DRUG
Intervention: polyethylene glycol + Electrolytes
Study NCT01348763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: Maraviroc 150 mg daily
Study NCT01348763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Truvada
Description: daily until 10. day then stop
Study NCT01348763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: daily until 10. day then stop
Study NCT02453971 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: German Version of eCHECKUP TO GO
Description: It is an online prevention program targeting alcohol consumption.
Study NCT02732899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Study NCT03904043 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Assessment of Cancer Therapy-Colorectal cancer (FACT-C) questionnaire
Description: -Baseline, completion of chemotherapy (3-8 weeks after the end of chemotherapy), and 10 to 14 months after radiotherapy
Study NCT03904043 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rectal biopsy samples
Description: -Multiple biopsy samples of the rectal tumor will be taken from the patient tumor prior to treatment initiation for genomic extraction. For patients at affiliate sites who do not have enough tissue from the diagnostic biopsy, a repeat pre-treatment biopsy is optional.
Study NCT03904043 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood for ctDNA
Description: -Prior to the start of treatment, Post radiation therapy labs (with standard of care (SOC) CBC/CMP prior to start of cycle 1 of chemotherapy), Day 1 of cycle 2 of chemotherapy (with SOC CBC/CMP), Completion of chemotherapy (3-8 weeks after the end of chemotherapy), 10-14 months after RT (if this visit aligns with a follow-up time point, one draw can be used to satisfy both time points), months 3, 6, 9, 12, 16, 20, 24 until salvage surgery or 2 years from completion of chemotherapy (whichever is first)
Study NCT00953927 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA85A/AERAS-485
Description: Attenuated virus MVA vector with insertion. Single dose vaccine, 1 x 10\^8 pfu.
Study NCT00953927 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Candida Skin Test Antigen
Description: 1 test, administered once as a placebo control.
Study NCT04289584 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength and proprioception exercises
Description: Strength and proprioception exercises will be performed with the athlete in different positions depending on the exercise. There will be 3 series with 30 repetitions and 10-second breaks between sets. Each exercise session will be held for 15 minutes. Theraband® exercises are: unipodal balancing on hard surface with open and closed eyes, unipodal balancing on soft surface, squats, lateral walk, isometric contractions with garter and dynamic leg opening, tiptoe, and eccentric hamstring curl with garter.
Study NCT01374906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pasireotide LAR
Description: Pasireotide long-acting was administered as an intra-muscular depot intragluteal injection once every 28 days (±2 days). Patients were administered pasireotide long-acting 10 mg or 30 mg for four months, followed by either continuation of the starting dose, or dose up-titration (if mUFC was still >1.5xULN unless titration was precluded by safety reasons).
Study NCT01374906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOM230 LAR 30 mg
Description: starting dose of 30 mg i.m. administered once every 28 days for 4 months, followed by dose up-titration or continuation of starting dose.
Study NCT01374906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOM230 LAR 10 mg
Description: starting does of SOM230 LAR 10 mg i.m. administered once every 28 days for 4 months, followed by dose up-titration or continuation of the starting dose.
Study NCT00068653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Celecoxib 400mg orally two times a day, taken with meals.
Study NCT00068653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD1839
Description: ZD1839 250 mg po every day, taken with or without food.
Study NCT01539291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: Idelalisib tablet(s) administered orally twice daily
Study NCT00057915 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CEA peptide 1-6D
Description: CAP-1(6D) peptide-pulsed, matured, autologous human DC produced by the AastromReplicell™ Cell Production System
Study NCT03994861 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Assessment of disability and behavior (by questionnaires)
Description: Assessment of disability and behavior (by questionnaires)
Study NCT03994861 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Assessment of disability and behavior (by questionnaires)
Description: Assessment of disability and behavior (by questionnaires)
Study NCT04296617 — intervention group
Intervention type: OTHER
Intervention: Medical Chart Review
Description: Review of medical chart
Study NCT00268528 — intervention group
Intervention type: BEHAVIORAL
Intervention: Compliance Monitoring
Description: Receive an electronic pill monitoring system comprising an empty MEMS medication bottle with TrackCap
Study NCT00268528 — intervention group
Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00268528 — intervention group
Intervention type: DRUG
Intervention: Mercaptopurine
Description: Given PO
Study NCT00268528 — intervention group
Intervention type: DRUG
Intervention: Methotrexate
Description: Given PO
Study NCT00268528 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT00268528 — intervention group
Intervention type: OTHER
Intervention: Study of Socioeconomic and Demographic Variables
Description: Receive an electronic pill monitoring system comprising an empty MEMS medication bottle with TrackCap
Study NCT02709967 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Material support
Description: Writing materials
Study NCT02709967 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Material support
Description: Writing materials
Study NCT02709967 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Economic
Description: Economic support (monthly cash transfer to girls, annual grant to guardians, and payment of school fees in grade 8 and 9)
Study NCT02709967 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community dialogue
Description: Community dialogue (youth club meetings, community and parent meetings)
Study NCT03468439 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Femoral nerve block with phenol
Study NCT04681521 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hot and Cold compress, nursing interventions
Description: using thermal compress at 38-39 °C (hot) and 15-16 °C (cold) on the distal regions of both lower extremities of the patients
Study NCT04681521 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hot and Cold compress, nursing interventions
Description: using thermal compress at 38-39 °C (hot) and 15-16 °C (cold) on the distal regions of both lower extremities of the patients
Study NCT04660981 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Antenatal education
Description: Training Program on Fear of Childbirth Based on Motivational Interview Method
Study NCT04201834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: capsule or tablet, 0.5 mg
Study NCT02732899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EYLEA
Study NCT02732899 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EYLEA
Study NCT03942718 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will obtain an individualized exercise program based on entrance examination on treadmill.
Study NCT00844454 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: multi-pronged ethanol ablation
Description: Under ultrasound guidance, insert an applicator into the tumor percutaneously and then inject ethanol to destroy the whole tumor tissue.
Study NCT00844454 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radiofrequency ablation
Description: Under ultrasound guidance, insert an applicator into the tumor percutaneously and then deliver radiofrequency energy to destroy the whole tumor tissue.
Study NCT01953406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 5-fluorouracin 15mg/kg/day D1-6 civ till progression, every 4 weeks
Study NCT01953406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin
Description: Mitomycin 4mg/day iv push D1,4 till progression, every 4 weeks
Study NCT05242679 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial release technique along with conventional physiotherapy exercises
Description: Myofascial release technique was performed using a tennis ball along with conventional physiotherapy exercises.
Study NCT04201834 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioStamp nPoint device
Description: MC10 has developed the BioStamp nPointTM, a FDA 510(k) cleared medical device. This multimodal, reusable and rechargeable biosensor uses flexible and stretchable electronics to enable unobtrusive wear on the body and monitoring in the home. The sensors have accelerometry, gyroscopy, and ECG/EMG capabilities. A docking station enables wireless recharging and data collection.
Study NCT05242679 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy exercises
Description: Conventional physiotherapy exercises were performed including the range of motion/flexibility exercises, strength training, postural control, functional exercises, and gait training.
Study NCT02290665 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thermosensitive gel rectal formulation
Study NCT02290665 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline enema
Study NCT00182689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally
Study NCT04474184 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Receive vaginal kit for biospecimen collection
Study NCT00639639 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tetanus toxoid
Description: Given by injection
Study NCT00639639 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic autologous dendritic cells
Description: Given intradermally
Study NCT04474184 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Focus Group
Description: Attend focus group
Study NCT04474184 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT03574129 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adolescent Transition Package
Description: Clinic level intervention composed of an adolescent transition package with tools to support health care workers to disclose HIV status to adolescents and to track transition to adult care.
Study NCT01389908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olanzapine
Description: Patients will receive doses within the range of 280 mg to 405mg OP Depot, according the physician's judgment, on a 3-week interval.
Study NCT01806480 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Person-centred proactive breastfeeding telephone support
Description: Person-centred care is a model of care, which comprise components such as: building mutual trust and understanding; treating the person as an individual; respect the rights for the person, sharing decision-making, providing holistic care and developing therapeutic relationships. Furthermore, the care provider should have a sympathetic presence and show an engagement
Study NCT02055352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Budesonide 400 mcg twice a day via Breezhaler® device
Study NCT02055352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone
Description: Fluticasone 250 mcg twice daily via Accuhaler® device
Study NCT02055352 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone
Description: Fluticasone 250 mcg twice daily via Accuhaler® device
Study NCT02055352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: Indacaterol 150 mcg once daily via Breezhaler® device
Study NCT02055352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol
Description: Salmeterol 50 mcg twice daily via Diskus® device
Study NCT02055352 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol
Description: Salmeterol 50 mcg twice daily via Diskus® device
Study NCT01858454 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HALS
Description: In HALS, a trocar of 5-mm calipers was inserted through the umbilicus. Next, suprapubic transverse skin incision of 3-4cm in length was made and a wound retractor (Alexis; Applied Medical, Rancho Santa Margarita, CA) was inserted through the suprapubic opening.
Study NCT01858454 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open surgery
Description: In open surgery, the patient was placed in the supine position and the operation was carried out in a standard manner as described elsewhere \[Luciano AA. Myomectomy. Clin Obstet Gynecol 2009;52:362-71.\].
Study NCT00796718 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Standard radiotherapy
Description: Administered as prescribed according to normal clinical practice.
Study NCT00796718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine [Xeloda]
Description: 825 milligrams per meter square (mg/m\^2) orally twice daily for 5 weeks.
Study NCT00648232 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Voluntary brief HIV counseling and testing
Description: Participants will receive 10 to 15 minutes of pretest counseling on the importance of HIV testing and on available services for people infected with HIV. After pretest counseling, participants will undergo a blood draw for HIV testing. Participants will receive test results and additional counseling 1 hour after the blood sample is drawn.
Study NCT00648232 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Voluntary brief HIV counseling and testing
Description: Participants will receive 10 to 15 minutes of pretest counseling on the importance of HIV testing and on available services for people infected with HIV. After pretest counseling, participants will undergo a blood draw for HIV testing. Participants will receive test results and additional counseling 1 hour after the blood sample is drawn.
Study NCT00648232 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Voluntary longer, more detailed HIV counseling and testing
Description: Participants will receive 45 to 60 minutes of pretest counseling on general HIV/AIDS information and testing for HIV. After pretest counseling, participants will undergo a blood draw for HIV testing. Participants will receive test results and additional counseling 1 hour after the blood sample is drawn.
Study NCT00648232 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Voluntary longer, more detailed HIV counseling and testing
Description: Participants will receive 45 to 60 minutes of pretest counseling on general HIV/AIDS information and testing for HIV. After pretest counseling, participants will undergo a blood draw for HIV testing. Participants will receive test results and additional counseling 1 hour after the blood sample is drawn.
Study NCT00648232 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced linkage to care
Description: Participants will be provided with more detailed counseling on how to access HIV services, will be introduced to a specific HIV clinic, and will be given a list of other HIV services available in the area. After leaving the hospital, participants will receive reminder telephone calls 1 week before their scheduled visits at the HIV clinics.
Study NCT02133911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Study NCT01256398 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Given IV
Study NCT00648232 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine referral to care
Description: Participants will be provided with information on the importance of receiving HIV care and will be given a list of available HIV area services.
Study NCT01490177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Food proteins
Description: Oral ingestion of Food proteins
Study NCT01256398 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo peripheral blood allogeneic HCT
Study NCT01256398 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo peripheral blood autologous HCT
Study NCT04352010 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Res-Up!
Description: Res-Up! is an internet-based intervention focusing on patients' strengths and positive experiences that have effects on distress, protective factors and quality of life. The intervention is based on the Personal Model of Resilience (PMR; Padesky and Mooney, 2012), which is a positive intervention that utilizes patients' strengths to overcome problems.The PMR activates resilient emotions, thoughts, metaphors, images and behaviors in four steps during five sessions about the aquisition of resilient strategies and their use in daily life. A variety of elements based on different psychotherapy approaches (Cognitive Behavioral Therapy, Emotion Focused Therapy, Positive Therapy etc.) are integrated in the program. Participants should work through one module per week. The intervention is conducted as I-CBT via the platform Minddistrict.Res-Up! is administered as a standalone or an add-on treatment to psychotherapy.
Study NCT04352010 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REMOTION
Description: REMOTION is an internet-based intervention aimed at transdiagnostically reducing symptom severity and improving emotion regulation of psychotherapy patients. The structure of REMOTION is based on the idea of an extended process model of emotion regulation as postulated by J.J. Gross (2015). The program includes the following modules: introduction, psychoeducation, identification, selection, implementation and modification. A variety of elements based on different psychotherapy approaches (Cognitive Behavioral Therapy, Emotion Focused Therapy, Dialectical Behavior Therapy etc.) are integrated in the program. Participants should work through one module per week. REMOTION is administered as a standalone or an add-on treatment to psychotherapy.
Study NCT04352010 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wait-Control Group
Description: In the waiting control group participants will answer questionnaires and they will gain access to either REMOTION or Res-Up! after twelve weeks.
Study NCT02157311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Four consecutive days on treatment and 3 days off
Description: All patients will take a combination of three of these treatment with a weekly strategy of 4 consecutive days on treatment followed by 3 days off treatment
Study NCT00384085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glulisine
Description: Subcutaneous injection up to 1 injection per day
Study NCT00384085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: Subcutaneous injection once-a-day
Study NCT00384085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Premixed Insulin
Description: Subcutaneous injection twice-a-day.
Study NCT00384085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glulisine
Description: Subcutaneous injection up to 3 injections per day.
Study NCT02842775 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: balance perturbation training
Description: perturbation training on the split-belt balance perturbance treadmill,
Study NCT01256398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT01256398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study NCT01256398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given PO
Study NCT01256398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin Hydrochloride
Description: Given IV
Study NCT00423436 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Questionnaires taking about 30-45 minutes to complete.